Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Decreases By 10.8%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 4,140,000 shares, a decrease of 10.8% from the October 15th total of 4,640,000 shares. Currently, 17.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 279,500 shares, the short-interest ratio is currently 14.8 days.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KALV. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, August 22nd.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, Director Albert Cha sold 18,000 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $10.50, for a total transaction of $189,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its holdings in KalVista Pharmaceuticals by 2.6% in the second quarter. Suvretta Capital Management LLC now owns 2,034,506 shares of the specialty pharmaceutical company’s stock worth $18,311,000 after buying an additional 51,327 shares during the last quarter. BlackRock Inc. boosted its holdings in KalVista Pharmaceuticals by 2.1% in the third quarter. BlackRock Inc. now owns 1,706,148 shares of the specialty pharmaceutical company’s stock worth $24,757,000 after purchasing an additional 34,653 shares in the last quarter. Boxer Capital LLC bought a new stake in KalVista Pharmaceuticals in the first quarter worth $12,969,000. Great Point Partners LLC increased its position in KalVista Pharmaceuticals by 51.6% during the first quarter. Great Point Partners LLC now owns 1,600,545 shares of the specialty pharmaceutical company’s stock worth $12,580,000 after buying an additional 544,744 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 1,166,652 shares of the specialty pharmaceutical company’s stock valued at $17,196,000 after buying an additional 28,168 shares in the last quarter.

KalVista Pharmaceuticals Stock Up 5.8 %

KalVista Pharmaceuticals stock traded up $0.44 during trading hours on Friday, hitting $8.05. The company had a trading volume of 233,141 shares, compared to its average volume of 266,870. KalVista Pharmaceuticals has a fifty-two week low of $4.95 and a fifty-two week high of $11.45. The firm’s fifty day moving average is $9.03 and its 200-day moving average is $9.68.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, September 7th. The specialty pharmaceutical company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.12. On average, research analysts predict that KalVista Pharmaceuticals will post -2.83 EPS for the current fiscal year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.